Management of Glioblastoma Multiforme in HIV Patients: a Case Series and Review of Published Studies

Hall, J.; Short, Susan

doi:10.1016/j.clon.2009.04.006

Cited by 27 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A relation of CD4 + counts with outcomes of patients with glioblastomas has been previously described. Hall and Short reported a median survival of 8 months in 16 HIV-positive patients who developed glioblastoma and had a serum median CD4+ count of 400 cells/μl (reference values 500-1500 cells/μl) (Hall and Short, 2009). Hughes et al measured postoperative CD4+ counts in peripheral blood during radiotherapy in patients with WHO grade III and IV gliomas receiving high dose steroids and found a worse OS in patients with low CD4+ counts but the difference was not statistically significant.…”

Section: Discussionmentioning

confidence: 98%

Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas

Gousias¹,

Ruecker²,

Simon³

2013

Journal of Neuroimmunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas

Gousias¹,

Ruecker²,

Simon³

2013

Journal of Neuroimmunology

View full text Add to dashboard Cite

“…Two cases received temozolomide and the treatment was well tolerated. A slight drop in lymphocyte count below normal was noted in both cases, but eventually returned to baseline levels [11]. …”

Section: Resultsmentioning

confidence: 99%

Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme

Choy

Lagman

Lee

et al. 2016

Brain Tumor Res Treat

View full text Add to dashboard Cite

BackgroundImprovement in antiviral therapies have been accompanied by an increased frequency of non-Acquired Immune Deficiency Syndrome (AIDS) defining malignancies, such as glioblastoma multiforme. Here, we investigated all reported cases of human immunodeficiency virus (HIV)-positive patients with glioblastoma and evaluated their clinical outcomes. A comprehensive review of the molecular pathogenetic mechanisms underlying glioblastoma development in the setting of HIV/AIDS is provided.MethodsWe performed a PubMed search using keywords “HIV glioma” AND “glioblastoma,” and “AIDS glioma” AND “glioblastoma.” Case reports and series describing HIV-positive patients with glioblastoma (histologically-proven World Health Organization grade IV astrocytoma) and reporting on HAART treatment status, clinical follow-up, and overall survival (OS), were included for the purposes of quantitative synthesis. Patients without clinical follow-up data or OS were excluded. Remaining articles were assessed for data extraction eligibility.ResultsA total of 17 patients met our inclusion criteria. Of these patients, 14 (82.4%) were male and 3 (17.6%) were female, with a mean age of 39.5±9.2 years (range 19–60 years). Average CD4 count at diagnosis of glioblastoma was 358.9±193.4 cells/mm3. Tumor progression rather than AIDS-associated complications dictated patient survival. There was a trend towards increased median survival with HAART treatment (12.0 vs 7.5 months, p=0.10)ConclusionOur data suggests that HAART is associated with improved survival in patients with HIV-associated glioblastoma, although the precise mechanisms underlying this improvement remain unclear.

show abstract

“…Gliomas, particularly glioblastoma multiforme (GBM), are the most common primary brain tumors in the non-HIV positive adult population and also account for a significant number of HIV patients with an intracerebral mass [160,161]. Not only is the incidence of glioma increased in patients with HIV, the average age of onset is significantly younger [152]. The role of the immune system in controlling the development and progression of cancers is well documented.…”

Section: Tumors Of the Brainmentioning

confidence: 99%

“…Approximately ten percent of patients with HIV will develop an intracerebral mass [152]. Primary central nervous system lymphoma (PCNSL) is diagnosed in 1.6-9.0% of patients with AIDS [153,154] and represents the second most common intracranial mass lesion in this population.…”

Section: Tumors Of the Brainmentioning

confidence: 99%

Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction

Grovit-Ferbas

Harris-White

2010

Immunol Res

View full text Add to dashboard Cite

It is estimated that half of HIV-infected adults and children will present at one time during their disease course with a neurologic disorder. The neurologic sequelae of HIV infection arise as a direct result of viral replication as well as from the subsequent neuroinflammatory processes. HIV enters the CNS early in infection and resides primarily in long-lived perivascular macrophages and microglia. CNS immunosurveillance is an integral part of normal brain function. Circulating lymphocytes play a vital role in support of brain plasticity under normal and traumatic circumstances. Malfunctions of this immunologic niche can impair brain homeostasis, resulting in neural impairment. Combination therapies that lower CNS viral load and improve immune homeostasis and neuroprotection will be required to address the neuropathogenesis of HIV infection.

show abstract

Management of Glioblastoma Multiforme in HIV Patients: a Case Series and Review of Published Studies

Cited by 27 publications

References 25 publications

Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas

Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas

Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme

Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction

Contact Info

Product

Resources

About